Maiwei Biology (688062.SH): Application for market approval of 9MW0813 injection has been accepted.
Maxwell Biosciences (688062.SH) announced that recently the company received approval and issuance from the National Medical Products Administration...
Medview Bio (688062.SH) announced that the company recently received an "Acceptance Notice" issued by the National Medical Products Administration for the approval of the marketing license application for 9MW0813 injection. It is intended for the treatment of diabetic macular edema (DME) and neovascular (wet) age-related macular degeneration (nAMD).
It is reported that 9MW0813 injection is a biosimilar of aflibercept (Eylea), a fusion protein formed by the extracellular binding domain of VEGFR-1 and VEGFR-2 with the Fc segment of human immunoglobulin, capable of binding to VEGF-A and PlGF.
Related Articles
DETAI NEWENERGY (00559) Announces Profit Growth; Estimated annual net profit of approximately HK$30 million to HK$35 million.
INNOVENT BIO (01801): Masidudipeptide has been approved by the China National Medical Products Administration for blood sugar control in adult type 2 diabetes patients.
YURUN FOOD (01068): Chen Xiaomi appointed as company secretary and authorized representative.
DETAI NEWENERGY (00559) Announces Profit Growth; Estimated annual net profit of approximately HK$30 million to HK$35 million.
INNOVENT BIO (01801): Masidudipeptide has been approved by the China National Medical Products Administration for blood sugar control in adult type 2 diabetes patients.
YURUN FOOD (01068): Chen Xiaomi appointed as company secretary and authorized representative.
RECOMMEND
Three-Year R&D Spend Drains RMB 2.4 Billion, Urgent Cash Needs Drive Maiwei Biotech Back to Hong Kong Amid Compliance Scrutiny
18/09/2025
Why Generating Profit Remains Challenging for Lidar Companies
18/09/2025
SEC Adopts Landmark Rule to Restrict Shareholder Class Actions in Bid to Revive IPO Market
18/09/2025
